Journals / İnfeksiyon Dergisi / 2004 / Cilt: 18 - Sayı: 3

Streptococcus intermedius group as pleural empyema agent: Case report

Ampiyem etkeni olarak Streptococus intermedius grup: Olgu sunumu

Pages
343–346
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, recognising the clinical, microbiological properties of S. intermedius group will bring a benefitial approach to the management of infections caused by these bacteria.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Streptococcus intermedius group has been introduced among viridans streptococci and in today's taxonomy is the most recently accepted group name of three distinct Streptococcus species (S. anginosus, S. constellatus and S. intermedius).
📊
Key Findings & Data:A 47-years-old male patient, presenting with pneumonia symptoms, was treated with gentamicin, after progressing to pleural empyema he was treated with gentamisin and sefazolin, and in another medical center treated with penicillin G and clindamycin.
💡
Conclusion & Impact:In conclusion, recognising the clinical, microbiological properties of S. intermedius group will bring a benefitial approach to the management of infections caused by these bacteria.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Streptococcus intermedius group has been introduced among viridans streptococci and in today's taxonomy is the most recently accepted group name of three distinct Streptococcus species (S. anginosus, S. constellatus and S. intermedius). Previously this agent had been named as "Streptococus milleri group". Since this nomenclature is now, it is difficult to identify this group in many clinical microbiology laboratories. In this study, discussion of the clinical and microbiological features of "S. intermedius group" agents causing pleural empyema is aimed. A 47-years-old male patient, presenting with pneumonia symptoms, was treated with gentamicin, after progressing to pleural empyema he was treated with gentamisin and sefazolin, and in another medical center treated with penicillin G and clindamycin. Surgical drainage had been applied to the patient who had not responded to medical treatment., Ampicillin-sulbactam 6 g and amikacin 1000 mg had been given in combination. The bacterium, grown under anaerobic conditions in primary isolation from pus material, was minute, sweat-odored, non-hemolytical, and catalase negative. It grew in %5-7 COg atmosphere. The isolate was identified as S. milleri group with API 20 Streptococcus panels (bio Merieux). In conclusion, recognising the clinical, microbiological properties of S. intermedius group will bring a benefitial approach to the management of infections caused by these bacteria.

Özet

Streptococus intermedius grup, viridans streptokoklar arasında yer alan ve sınıflandırmada üç ayrı streptokok (S. anginosus, S. constellatus ve S. intermedius) türüne verilen en güncel grup adıdır. Önceleri "Streptococcus milleri grup" olarak adlandırılırdı. Bu grubun adının çok yeni olması, bu etkenlerin birçok laboratuvarda tanınmasını güçleştirmektedir. Bu çalışmada, invazif irinli infeksiyonlara yol açabilen "S. intermedius grup" etkeninin, bir plöra ampiyemi olgusu nedeniyle, klinik ve mikrobiyolojik özelliklerinin değerlendirilmesi amaçlanmıştır. Pnömoni klinik tablosuyla başvuran 47 yaşında erkek hastaya, sırasıyla gentamisin, plöra ampiyemi gelişmesinden sonra gentamisin ve sefazolin ve başka bir tıp merkezinde penisilin G ve klindamisin verildi. Bu tıbbi tedaviden yarar görmeyen hastaya kapalı su altı drenajı uygulandı ve ampisilin-sulbaktam 6 g ve amikasin 1000 mg kombinasyon tedavisine başlandı, irinden alınan örnekte ilk izolasyonda anaerop koşullarda üreyen bakterinin, iğne ucu büyüklüğünde, tatlımsı kokulu, non-hemolitik koloni oluşturduğu ve katalaz testinin olumsuz olduğu belirlendi. Pasajlarda bakterinin %5-7 CO2'Iİ ortamda ürediği gözlendi. Köken API 20 Streptokok panelleri (bio Merieux) ile S. milleri grup olarak tanımlandı. Sonuç olarak, S. intermedius grup organizmalarının klinik ve mikrobiyolojik özelliklerinin iyi tanınması, bu etkenlerle oluşan infeksiyonlara karşı antimikrobik tedavi yaklaşımlarını da belirlemiş olacaktır.

🔖

Cite This Article

ÖNEN, A., KEBAPÇILAR, L., COŞKUNER, A., ÖZGENÇ, O. (2022). Streptococcus intermedius group as pleural empyema agent: Case report. İnfeksiyon Dergisi, Cilt: 18 - Sayı: 3, 343–346. https://ajindex.com/articles/546549

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Antony SJ, Stratton CW. Streptococcus intermedius Group. İn: Mandell GL, Bennett Jl, Dolin R, edrs. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill and Livingstone, 2000: 2183-7
  2. Jacobs JA, Pietersen HG, Stobberingh EE, Soeters PB. Streptococcus anginosus, Streptococcus constellatus and Streptococcus intermedius. Clinical relevance, hemolytic and serologic characteristcs. Am J Clin Pathol 1995; 104: 547-53
  3. Bert F, Bariou-Lancelin M, Lambert-Zechovsky N. Clinical significance of bacteremia involving the "Streptococcus milleri" group: 51 cases and review. Clin Infect Dis 1998; 27: 385-7
  4. Bantar C, Fernandez CL, Relloso S, Lanza A, Bianchini H, Smayevsky J. Species belonging to the "Streptococcus milleri" group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens. J Clin Microbiol 1996; 34: 2020-2
  5. Shinzato T, Saito A. The Streptococcus milleri group as a cause of pulmonary infections. Clin Infect Dis 1995; 21 (Suppl 3): S238-43
  6. Wong CA, Donald F, Macfarlane JT. Streptococcus milleri pulmonary disease. A review and clinical description of 25 patients. Thorax 1995; 50: 1093-6
  7. Galea JL, De Souza A, Beggs D, Spyt T. The surgical management of empyema thoracis. J R Coll Surg Edinb 1997; 42:15-8
  8. File TM, Tan JS. Incidence, ethiologic pathogens, and diagnostic testing of community-acquired pnemonia. CurrOpin Pulm Med 1997; 3: 89-97
  9. Brogan O, Malone J, Fox C, Whyte AS. Lancefield grouping and smell of caramel for presumptive identification and assessment of pathogenicity in the Streptococcus milleri group. J Clin Pathol 1997; 50: 332-5
  10. Porta G, Rodriguez-Carballeira M, Gomez L, et al. Thoracic infection caused by Streptococcus milleri. Eur Respir J1998; 12: 357-62
  11. Flynn CE, Ruoff KL. Identification of "Streptococcus milleri' group isolates to the species level with a commercially available rapid test system. J Clin Microbiol 1995; 33: 2704-6
  12. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC. Color Atlas and Textbook of Diagnostic Microbiology. 5th ed. Philadelphia: Lippincott, 1997: 592-614
  13. Jacobs JA, Pietersen HG, Stobberngh EE, Soeters PB. Bacteremia involving the "Streptococcus milleri" group: analysis of 19 cases. Clin Infect Dis 1994; 19: 704-13
  14. Casariego E, Rodriguez A, Corredoira JC, et al. Prospective study of Streptococcus milleri bacteremia. Eur J Clin Microbiol Infect Dis 1996; 15:194-200.